APPLICATIONS PUBLISHED 2 JANUARY 2004
Published: 1-Jun-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Facially amphiphilic polymers as anti-infective agents
The University of Pennsylvania 1372551*
Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use
Microvention 1372553*
Manufacturing dissolvable dosage forms
Battelle Memorial Institute 1372604*
Intravaginal drug delivery devices for the administration of an antimicrobial agent
Galen (Chemicals) 1372605*
In-situ gel formation of pectins
Carrington Laboratories 1372606*
Adjuvant emulsion and method of using said emulsion
Exner, Heinrich 1372607*
Medical aerosol formulations
Jagotec 1372608*
Peat product compsn, method for the production and use thereof
Humadern 1372609*
Powder inhaler formulations
Boehringer Ingelheim Pharmaceuticals 1372610*
Pharmaceutical compsn comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
Novartis 1372611*
A pharmaceutical tablet system that floats on gastric fluid for multipulse release of active substances, and respective processes of producing same and a cup-shaped envelope of same
Jagotec 1372612*
A confectionery product having a salivation region and an oral comfort region
Mars 1372613*
Controlled release sulfonylurea formulation
Andrx Corp 1372614*
Compounds and compsns for delivering active agents
Emisphere Technologies 1372615*
A stable pharmaceutical compsn of pravastatin
Ranbaxy Laboratories 1372616*
Enteric ketoacid salts and amino acids and their use for preparing medicines
Chiesi 1372617*
Colloidal suspension of nanoparticles based on an amphiphilic copolymer
Flamel Technologies 1372618*
Highly flexible transdermal therapeutic system having nicotine as active substance
LTS Lohmann Therapie-Systeme 1372619*
Methods for restoring cognitive function following systemic stress
Saegis Pharmaceuticals 1372620*
Novel use of tyrosine kinase inhibitor
Innoventus Project 1372621*
Parasiticidal compsns and methods of use
Schering-Plough 1372622*
Control of parasitic mites of honey bees
The United States of America, represented by the Secretary of Agriculture 1372623*
Tramadol-based medicament
Gruenenthal 1372624*
Uses of benzylideneamino guanidines as ligands to the melanocortin receptors
Melacure Therapeutics 1372625*
Compsns and methods for enhancing drug delivery across and into ocular tissues
Cellgate 1372626*
Use of breakers of advanced glycation end products for treating deleterious effects of ageing and debilitating diseases
City of Hope 1372627*
Paracetamol solutions which are stable in storage and ready for infusion
Sommermeyer, Klaus 1372628*
Therapeutic treatment
Ernst, Pieter Theo 1372629*
Agent for the treatment of overactive bladder
Kyowa Hakko Kogyo; University of Pittsburgh 1372630*
Method and formula for anti-tumour and anti-metastatic effect
Giles, Brian 1372631*
Proliferative activator receptor (PPAR) compounds
Pfizer 1372632*
Irrigating fluid
Aga 1372633*
Fumaric acid amides
Fumapharm 1372634*
Use of creatine for the amelioration of oxidative stress
2458781 Canada 1372635*
Metronomic dosing of taxanes for inhibiting tumour growth
Bristol-Myers Squibb 1372636*
Premixed amiodarone parenteral solution and method of making the same
Baxter International 1372637*
Functional role for cannabinoids in autonomic stability during sleep
The Board of Trustees of the University of Illinois 1372638*
Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
Kyowa Hakko Kogyo; University of Pittsburgh 1372639*
Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
Aventis Pharma Deutschland 1372640*
Enteral formulation
Ernest, Stephen 1372641*
Use of pyrazolopyridines as therapeutic compounds
SmithKline Beecham 1372642*
Pyrazolopyridines, process for their preparation and use as therapeutic compounds
SmithKline Beecham 1372643*
Use of substituted imidaz 1,2-(A)-pyridine-3-yl-amine and imidazo 1,2-(A)-pyridine-3-yl-amine compounds as medicaments
Gruenenthal 1372644*
Reconstitutable parenteral compsn containing a COX-2 inhibitor
Pharmacia Corp 1372645*
Use of sugar phosphates, sugar phosphate analogues, amino acids, amino acid analogues for modulating transaminases and/or the association of p36/malate dehydrogenase
Schebo Biotech 1372646*
Use of substituted imidazo 1,2-(A)-pyridine compounds as medicaments
Gruenenthal 1372647*
TIE2 receptor kinase inhibitors for treating angiogenic diseases
SmithKline Beecham 1372648*
Novel medicament compsns on the basis of anticholinergics and PDE IV inhibitors
Boehringer Ingelheim 1372649*
Combinations comprising an antidiarrheal agent and an epithilone or an epithilone derivative
Novartis 1372650*
Novel amides, preparation and therapeutic use as modulators of CCR-receptor activity
AstraZeneca 1372651*
Combination of a taxane and a cyclin-dependent kinase
Aventis Pharma 1372652*
Acylated piperidine derivatives as melanocortin-4 receptor agonists
Merck 1372653*
Quinoline inhibitors of HYAK1 and HYAK3 kinases
SmithKline Beecham 1372654*
Cathepsin cysteine protease inhibitors
Merck Frosst Canada; Axys Pharmaceuticals 1372655*
Pyrazolo[4,3-D]pyrimidinone compounds as CGMP PDE inhibitors
Pfizer 1372656*
A method of treating proliferative diseases using EG5 inhibitors
Bristol-Myers Squibb 1372657*
Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacytabine
Shire Biochem 1372658*
Substances for use in therapy of diseases that are caused by highly proliferative cells
Schmalz, Hans-Guenther; Universitaetsklinikum Charite Medizinische Fakultaet der Humboldt-Universitaet zu Berlin 1372659*
A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
Metabasis Therapeutics; Sankyo Company 1372660*
Methods of treating irritable bowel syndrome and functional dyspepsia
SmithKline Beecham 1372661*
Taste masked liquid pharmaceutical compsns
Ortho-McNeil Pharmaceutical 1372662*
Therapeutic method involving subcutaneous administration of drugs containing cephalotaxine derivatives
Oncopharm Corp 1372663*
Use of certain steroids for treatment of blood cell deficiencies
Hollis-Eden Pharmaceuticals 1372664*
Hormone replacement therapy method and its administration form
Schering 1372665*
Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial/matrix adhesion such as asthma, cystic fibrosis and influenza
Glaxo Group 1372666*
Compsns for delivering bisphosphonates
Emisphere Technologies 1372667*
Compsns comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such compsn and use thereof
Gador 1372669*
Caloporoside derivatives, methods for the production thereof and their use
Aventis Pharma Deutschland 1372670*
Methylated promoters for intraductal treatment of breast cancer
Cytyc Health Corp 1372671*
